Grace TherapeuticsGRCE
13F holders, Q2 2026 (June 30)33holders −1
10new positions
11sold out
1famous investor
$2.27avg. 13F price*
At the end of Q2 2026, 33 institutions reported holding Grace Therapeutics Inc. (GRCE) in their 13F filings, down 1 from Q1 2026. 10 opened new positions and 11 sold out. The largest holders were Cerity Partners LLC ($1.9M), Eversept Partners, LP ($1.8M) and Bank of America Corp. ($1.1M). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Grace Therapeutics Inc.
- CUSIP
- 00439U104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $1.4M |
| Exits | 11 | $6.1M |
All 13F filers, Q1 2026 → Q2 2026: 980,215 shares bought and 1,394,895 shares sold, net −414,680 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 33 holders
| Cerity Partners LLC | 0.00% | No change | 849,055 | $1.9M |
| Eversept Partners, LP | 0.10% | Add +2.1% | 772,900 | $1.8M |
| Bank of America Corp. | 0.00% | Reduce -0.0% | 494,698 | $1.1M |
| Vanguard Capital Management LLC | 0.00% | Add +2.5% | 411,714 | $935K |
| Citadel Advisors | 0.00% | Add +254.2% | 349,740 | $794K |
| Maven Securities LTD | 0.03% | New | 200,000 | $454K |
| Birchview Capital, LP | 0.13% | Add +140.0% | 120,000 | $272K |
| Cantor Fitzgerald, L. P. | 0.00% | New | 100,000 | $227K |
| Two Sigma Investments, LP | 0.00% | New | 96,890 | $220K |
| Jane Street Group, LLC | 0.00% | Reduce -46.5% | 89,442 | $203K |
| XTX Topco Ltd | 0.00% | Add +13.6% | 71,668 | $163K |
| HRT Financial LP | 0.00% | New | 62,691 | $142K |
| Susquehanna International Group, LLP | 0.00% | New | 49,577 | $113K |
| BlackRock, Inc. | 0.00% | New | 37,535 | $85K |
| Rangeley Capital, LLC | 0.06% | New | 26,000 | $59K |
| Kestra Private Wealth Services, LLC | 0.00% | Add +76.9% | 23,000 | $52K |
| UBS Group AG | 0.00% | Reduce -36.2% | 16,777 | $38K |
| Stratos Investment Management, LLC | 0.00% | New | 11,158 | $25K |
| BNP Paribas Financial Markets | 0.00% | Add +47.9% | 10,500 | $24K |
| Scientech Research LLC | 0.02% | New | 10,184 | $23K |
| Virtu Financial LLC | 0.00% | New | 10,166 | $23K |
| Oppenheimer & Co. Inc. | 0.00% | No change | 10,000 | $23K |
| Morgan Stanley | 0.00% | Add +107.7% | 9,448 | $21K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 8,750 | $20K |
| National Bank of Canada | 0.00% | Reduce -1.3% | 2,680 | $6K |
| Wells Fargo & Company | 0.00% | No change | 1,800 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +298.1% | 1,652 | $4K |
| Arax Advisory Partners | 0.00% | Add +100.0% | 1,000 | $2K |
| Royal Bank of Canada | 0.00% | No change | 543 | $1K |
| Activest Wealth Management | 0.00% | No change | 104 | $236 |
| SBI Securities Co., Ltd. | 0.00% | Add +10.0% | 77 | $175 |
| Federation des caisses Desjardins du Quebec | 0.00% | Add +4000.0% | 41 | $93 |
| Lanark Financial, Inc. | 0.00% | No change | 2 | $4 |
"% of holder's portfolio" is GRCE's weight in each manager's 13F, not the share of Grace Therapeutics Inc. the manager owns.